Evidence map›Paper›PMID 21811626›Full record

Trial reportPloS one2011

The effect of pulmonary artery catheter use on costs and long-term outcomes of acute lung injury.

Gilles Clermont, Lan Kong, Lisa A Weissfeld, Judith R Lave, Gordon D Rubenfeld, Mark S Roberts, Alfred F Connors, Gordon R Bernard, B Taylor Thompson, Arthur P Wheeler and 2 more

Registry-linked trialOpen access · goldAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00234767 (Economic Analysis of Pulmonary Artery Catheter Use), which is not on this map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00234767 completednot on this map

Economic Analysis of Pulmonary Artery Catheter Use (EA-PAC)

TypeobservationalSponsorUniversity of PittsburghRan2001Enrolled650ConditionsAcute Respiratory Distress Syndrome, Acute Lung Injury, Lung DiseasesArmsPulmonary Artery Catheter, Protocolized Fluid Management
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Observational
  16. Article
  17. Article
  18. The pulmonary artery catheter.Journal of clinical monitoring and computing · 2012
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Gilles ClermontClinical Research, Investigation, and Systems Modeling of Acute Illness Center, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America. clermontg@upmc.edu
Lan Kong
Lisa A Weissfeld
Judith R Lave
Gordon D Rubenfeld
Mark S Roberts
Alfred F Connors
Gordon R Bernard
B Taylor Thompson
Arthur P Wheeler
Derek C Angus
NHLBI ARDS Clinical Trials Network
University of Pittsburgh · USVanderbilt University · USCase Western Reserve University · USHarvard University · USHealth Sciences Centre · CA

Funding

CENTER FOR CLINICAL NETWORK FOR ARDS TREATMENT-N01HR46064-268046064N01HR046064 · HR · MASSACHUSETTS GENERAL HOSPITAL · 1994 to 2005
$706k
Economic Analysis of Pulmonary Artery Catheter UseR01HS011620 · AHRQ · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ANGUS, DEREK C · 2001 to 2004
–
ULTRASENSITIVE IMMUNOASSAYS FOR CLOTTING FACTORSR43HL046064 · NHLBI · AMPLISTAR, INC. · PI DOELLGAST, GEORGE J · 1991 to 1991
–
AHRQ HHS R01 HS011620AHRQ HHS R01-HS-11620NHLBI NIH HHS N01 HR046064NHLBI NIH HHS N01-HR-46064
6 · The paper itself

Abstract

backgroundThe pulmonary artery catheter (PAC) remains widely used in acute lung injury (ALI) despite known complications and little evidence of improved short-term mortality. Concurrent with NHLBI ARDS Clinical Trials Network Fluid and Catheters Treatment Trial (FACTT), we conducted a prospectively-defined comparison of healthcare costs and long-term outcomes for care with a PAC vs. central venous catheter (CVC). We explored if use of the PAC in ALI is justified by a beneficial cost-effectiveness profile.

methodsWe obtained detailed bills for the initial hospitalization. We interviewed survivors using the Health Utilities Index Mark 2 questionnaire at 2, 6, 9 and 12 m to determine quality of life (QOL) and post-discharge resource use. Outcomes beyond 12 m were estimated from federal databases. Incremental costs and outcomes were generated using MonteCarlo simulation.

resultsOf 1001 subjects enrolled in FACTT, 774 (86%) were eligible for long-term follow-up and 655 (85%) consented. Hospital costs were similar for the PAC and CVC groups ($96.8k vs. $89.2k, p = 0.38). Post-discharge to 12 m costs were higher for PAC subjects ($61.1k vs. 45.4k, p = 0.03). One-year mortality and QOL among survivors were similar in PAC and CVC groups (mortality: 35.6% vs. 31.9%, p = 0.33; QOL [scale: 0-1]: 0.61 vs. 0.66, p = 0.49). MonteCarlo simulation showed PAC use had a 75.2% probability of being more expensive and less effective (mean cost increase of $14.4k and mean loss of 0.3 quality-adjusted life years (QALYs)) and a 94.2% probability of being higher than the $100k/QALY willingness-to-pay threshold.

conclusionPAC use increased costs with no patient benefit and thus appears unjustified for routine use in ALI.

trial registrationwww.clinicaltrials.gov NCT00234767.

Indexed as

Health Care CostsAcute Lung InjuryCatheterization, Central VenousCatheterization, Swan-GanzCohort StudiesComputer SimulationCost-Benefit AnalysisFemaleHumansMaleMiddle AgedMonte Carlo MethodPatient DischargeSensitivity and SpecificityTime FactorsTreatment Outcome

Identifiers

PMID21811626
PMCPMC3141060
OpenAlexW2106901270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.